In vitro studies also confirmed that rutaecarpine can inhibit NLRP3/ASC/IL-18/IL-1β in MPC-5 and reduce programmed cell necrosis, which suggested that rutaecarpine may be protective to DKD through NLRP3-dependent pathway. Here, IL18 is linked to diabetic kidney disease.